(Total Views: 171)
Posted On: 01/01/2019 9:47:44 PM
Post# of 36566
I’m not sure where Generex currently stands with patent protection regarding RapidMist, if you do a patent search I never saw 150 (perhaps Doc means how many molecules or etc that could be delivered), but regardless we did hear in the Feb 2017 CC this from Richard Purcell:
“Lastly, Generex owns a broad patent portfolio pertaining to its proprietary buccal spray delivery system. Dozens of companies are infringing on these patents so the company’s working with a law firm on a strategy to seek injunctive relief and damages for patent infringement. With its patent enforcement strategy Generex can realize significant royalty payment from sales of products that use buccal spray delivery.”
They may have said something similar in last January’s CC, and I suppose they’ll possibly update the patent relating specifically to buccal insulin since it’s an improved formulation. Just guessing there.
“Lastly, Generex owns a broad patent portfolio pertaining to its proprietary buccal spray delivery system. Dozens of companies are infringing on these patents so the company’s working with a law firm on a strategy to seek injunctive relief and damages for patent infringement. With its patent enforcement strategy Generex can realize significant royalty payment from sales of products that use buccal spray delivery.”
They may have said something similar in last January’s CC, and I suppose they’ll possibly update the patent relating specifically to buccal insulin since it’s an improved formulation. Just guessing there.
(0)
(0)
